TR

Trevi Therapeutics IncNASDAQ TRVI Stock Report

Last reporting period 30 Sep, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

0.23

Micro

Exchange

XNAS - Nasdaq

TRVI Stock Analysis

TR

Uncovered

Trevi Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.23

Dividend yield

Shares outstanding

60.045 B

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut. The company went IPO on 2019-05-07. The company is engaged in developing Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Haduvio is an oral extended-release (ER) formulation of nalbuphine. The company is conducting Phase IIb/3 clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. The company is also conducting Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as Phase II CANAL trial. The company has also commenced Phase Ib trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics of Haduvio. Its Haduvio development programs include Active Chronic Pruritus Programs, Prurigo Nodularis Program, and Chronic Cough in Idiopathic Pulmonary Fibrosis Program.

View Section: Eyestock Rating